Portfolio company Accession Therapeutics awarded €7.5M Horizon Europe grant funding for immuno-oncology research.
Accession Therapeutics is focused on treating some of the most intractable and widespread forms of cancer using its stealth virus platform technology, Trocept
Accession Therapeutics is focused on treating some of the most intractable and widespread forms of cancer using its stealth virus platform technology, Trocept. The company is developing a pipeline of highly targeted immuno-oncology products, with its first drug candidate, TROCEPT-01, currently in Phase 1 clinical trials.